{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-017924","form_type":"8-K","ticker":"ABT","cik":"0000001800","company_name":"ABBOTT LABORATORIES","filed_at":"2025-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.766293+00:00","generated_at":"2026-05-23T13:32:01.193877+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Abbott Q1 adjusted EPS $1.09, revenue $10.36B (+4% reported); reaffirms FY guidance","bullets":["GAAP diluted EPS $0.76; adjusted diluted EPS $1.09 (double-digit YoY growth).","Reported revenue $10.36B (+4.0%), organic sales +6.9% (+8.3% ex-COVID testing).","Medical Devices sales +9.9% reported (+12.6% organic); FreeStyle Libre revenue $1.7B.","Full-year 2025 adjusted EPS guidance reaffirmed: $5.05-$5.25; Q2 adj. EPS $1.23-$1.27.","Volt PFA System received CE Mark; TECTONIC IVL pivotal trial initiated in U.S."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-017924","json":"https://secwatch.observer/filing/0001628280-25-017924.json","markdown":"https://secwatch.observer/filing/0001628280-25-017924.md","text":"https://secwatch.observer/filing/0001628280-25-017924.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800/000162828025017924/0001628280-25-017924-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800/000162828025017924/abt-20250416.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T13:32:01.193877+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}